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Original ArticleInsulin-like growth factor-1 activates AMPK to
augment mitochondrial function and correct
neuronal metabolism in sensory neurons in type
1 diabetesMohamad-Reza Aghanoori 1,2, Darrell R. Smith 1, Shiva Shariati-Ievari 5, Andrew Ajisebutu 1, Annee Nguyen 3,
Fiona Desmond 3, Carlos H.A. Jesus 3, Xiajun Zhou 3, Nigel A. Calcutt 3, Michel Aliani 4,5,6,
Paul Fernyhough 1,2,*ABSTRACT
Objective: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately half of diabetic patients leading to significant morbidity. There is
impaired neurotrophic growth factor signaling, AMP-activated protein kinase (AMPK) activity and mitochondrial function in dorsal root ganglia
(DRG) of animal models of type 1 and type 2 diabetes. We hypothesized that sub-optimal insulin-like growth factor 1 (IGF-1) signaling in diabetes
drives loss of AMPK activity and mitochondrial function, both contributing to development of DSPN.
Methods: Age-matched control Sprague-Dawley rats and streptozotocin (STZ)-induced type 1 diabetic rats with/without IGF-1 therapy were
used for in vivo studies. For in vitro studies, DRG neurons from control and STZ-diabetic rats were cultured and treated with/without IGF-1 in the
presence or absence of inhibitors or siRNAs.
Results: Dysregulation of mRNAs for IGF-1, AMPKa2, ATP5a1 (subunit of ATPase), and PGC-1b occurred in DRG of diabetic vs. control rats.
IGF-1 up-regulated mRNA levels of these genes in cultured DRGs from control or diabetic rats. IGF-1 treatment of DRG cultures significantly
(P < 0.05) increased phosphorylation of Akt, P70S6K, AMPK and acetyl-CoA carboxylase (ACC). Mitochondrial gene expression and oxygen
consumption rate (spare respiratory capacity), ATP production, mtDNA/nDNA ratio and neurite outgrowth were augmented (P < 0.05).
AMPK inhibitor, Compound C, or AMPKa1-specific siRNA suppressed IGF-1 elevation of mitochondrial function, mtDNA and neurite
outgrowth. Diabetic rats treated with IGF-1 exhibited reversal of thermal hypoalgesia and, in a separate study, reversed the deficit in corneal
nerve profiles. In diabetic rats, IGF-1 elevated the levels of AMPK and P70S6K phosphorylation, raised Complex IV-MTCO1 and Complex
V-ATP5a protein expression, and restored the enzyme activities of Complex IV and I in the DRG. IGF-1 prevented TCA metabolite build-up
in nerve.
Conclusions: In DRG neuron cultures IGF-1 signals via AMPK to elevate mitochondrial function and drive axonal outgrowth. We propose that this
signaling axis mediates IGF-1-dependent protection from distal dying-back of fibers in diabetic neuropathy.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diabetic sensorimotor polyneuropathy (DSPN) frequently presents with
a stocking and glove distribution that is proposed to reflect the dying
back of the longest peripheral nerve fibers. Incidence can range from
10% to 90% in diabetic patients, depending on the criteria and
methods used to define neuropathy [1]. In humans and animal models
of type 1 and type 2 diabetes, the level of available insulin-like growth
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www.molecularmetabolism.comconsequence of suppressed expression in the liver [2e5]. Thus,
impaired neurotrophic support by insulin signaling and insulin-like
growth factors (IGF-1 and IGF-2) have been proposed to contribute
to neurodegeneration in diabetes [6e8]. In addition to a critical role for
IGF-1 during nervous system development and early postnatal growth
[9], IGF-1 promotes neurite outgrowth in sensory [10,11], motor [12]
and sympathetic [9,11] neurons. Further, Schwann cells also require
IGF-1 and IGF type 1 receptor signaling for survival, motility, cell
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1 improves the rate of sciatic nerve regeneration in age matched
control or streptozotocin (STZ)-induced type 1 diabetic rats [5,17,18].
Hyperalgesia was also prevented/reversed in STZ-induced diabetic
rats treated with IGF-1 [19]. Lumbar intrathecal injection of IGF-1
reversed indices of neuropathy including the deficit in intra-
epidermal nerve fiber (IENF) density, sural nerve axonal degenera-
tion, and reduced sensory and motor nerve conduction velocities in
STZ-induced type 1 diabetic rats [20,21]. Adenovirus-mediated IGF-1
expression via an intrathecal route or through the liver improved nerve
regeneration, myelination, and motor and sensory nerve conduction
velocities in mouse models of diabetic neuropathy [22,23]. Finally, IGF
binding protein 5, an endogenous inhibitor of IGF-1 action, is up-
regulated in sural nerve biopsies from persons with diabetic neurop-
athy, and its over-expression in transgenic mice induced motor and
sensory neuropathy [24]. Thus, there is extensive evidence of the
therapeutic potential of IGF-1 in animal models of diabetes. However,
less is known about the cellular mechanisms by which IGF promotes
neuroprotection in diabetes.
IGF type 1 receptor mobilizes two widely known pathways, the Akt/
phosphoinositide-3 kinase (PI-3K) and the mitogen-activated protein
(MAP) kinase pathways, mediated by insulin receptor substrate (IRS) 1
and IRS 2 phosphorylation following ligand binding [25,26]. The Akt/PI-
3K pathway activates the mammalian target of rapamycin (mTOR)
pathway, which directs protein synthesis and cell growth via down-
stream effectors, P70S6K and 4E-binding protein 1 (4E-BP1) [26]. The
MAPK pathway incorporates activation of extracellular signal-regulated
kinase (ERK)-1/2 and target transcription factors such as Elk-1 to
regulate cell survival [25]. IGF-1 also activates AMP-activated protein
kinase (AMPK) during osteoblast differentiation [27]. The AMPK-a
subunit is phosphorylated and activated by IGF-1 in an ataxia telan-
giectasia mutated (ATM)-dependent manner in a human pancreatic
cancer cell line [28]. Alternatively, IGF-1 suppresses AMPK activity in
vascular smooth muscle cells mediated through Akt1 which phos-
phorylates an inhibitory site on AMPK at S485 [29]. Any or all of these
pathways could be pertinent to the neuroprotective actions of IGF-1
against diabetic neuropathy.
It may be particularly pertinent that IGF-1 activates AMPK as the AMPK/
peroxisome proliferator-activated receptor g co-activator 1-a (AMPK/
PGC-1a) energy sensing pathway augments mitochondrial function in
a range of cell types [30]. A well-characterized upstream activator of
AMPK is Ca2þ/calmodulin-dependent protein kinase kinase b
(CaMKKb) [31]. A small range of studies have demonstrated that IGF-1
can regulate cellular metabolism and bioenergetics in neurons and
astrocytes and protect against Huntington’s disease [32e35]. In hu-
man tissues derived from persons with diabetes there is down-
regulation of the AMPK/PGC-1a pathway [36,37]. In animal models
of DSPN, the levels of expression and activity of AMPK and PGC-1a are
also significantly depressed in the dorsal root ganglia (DRG). Under
hyperglycemic conditions it has been proposed that nutrient stress
triggers this down-regulation of AMPK [38]. However, the mechanistic
interactions between IGF-1, AMPK and mitochondrial function are
poorly defined and the contribution of impaired IGF-1 signaling and
associated pathways to the pathogenesis of DSPN remain to be
characterized. We therefore investigated whether exogenous IGF-1
could optimize AMPK activity and mitochondrial function to promote
axonal repair in sensory neurons derived from the DRG of rodents with
type 1 diabetes and combined this with assessment of the impact of
IGF-1 on indices of small sensory fiber neuropathy in two rodent
models of type 1 diabetes.150 MOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. T2. MATERIALS AND METHODS
2.1. Induction of type 1 diabetes
Male Sprague-Dawley rats were obtained from a breeding colony at
the University of Manitoba at a weight of 201e225 g and maintained 2
per cage on Sani-Chips bedding (P.J. Murphey, Montville, NJ, USA) in a
Canadian Council of Animal Care (CCAC)-accredited vivarium under a
12 hr light:dark cycle with free access to diet (5001, LabDiet with fat
content of not less than 4.5%, MO, USA) and municipal water. A
randomly selected cohort of rats (275e325 g) were made diabetic
(non-fasting blood glucose > 19 mmol/l) by a single 90 mg/kg i.p.
injection of STZ (Sigma, St. Louis, MO, USA) as previously described
[39]. A randomly selected cohort (N ¼ 12) of 3-month STZ-induced
diabetic rats received thrice-weekly subcutaneous injections of
20 mg IGF-1 (recombinant human, Preprotech Inc., Rocky Hill, NJ, USA)
per rat between 9 AM and 11 AM as previously described [40] for 11
weeks. Fasting blood glucose concentration was monitored half way
through the injection period and at study end using an AlphaTRAK
glucometer (Abbott Laboratories, Illinois, USA) to ensure that IGF-1
injection did not affect hyperglycemia. At the end of 24 weeks,
blood glucose, glycated hemoglobin (HbA1c Multi-test system,
HealthCheck Systems, Brooklyn, NY, USA) and body weight were
recorded before tissue collection (Supplemental Table 1). No rats died
during the study period, no rats required insulin supplementation to
offset extreme weight loss, and, at study end, all STZ-injected rats
remained hyperglycemic (non-fasting blood glucose > 19 mmol/l).
Animal procedures were approved by the University of Manitoba Ani-
mal Care Committee and followed CCAC rules.
2.2. Hind paw thermal sensitivity test in adult rats
Hind paw thermal response latencies were measured using a Har-
greaves apparatus (UARD, La Jolla, CA, USA) as previously described
[41]. Briefly, between 9 AM and 3 PM, rats were placed in plexiglass
cubicles on top of the thermal testing system. The heat source was
placed below the middle of one of the hind paws and latencies of the
paw withdrawal to the heat source were automatically measured.
Response latency of each paw was measured three times at 5 min
intervals and the mean values were determined.
2.3. Intra-epidermal nerve fiber density in hind paw footpads
The plantar dermis and epidermis of the hind paw were removed and
placed in 4% paraformaldehyde. Tissue was coded, processed to
paraffin blocks, cut as 6 mm sections, immunostained using an
antibody to PGP 9.5 (1:1000, Biogenesis Ltd. Poole, UK) and the
number of immunoreactive IENF and sub-epidermal nerve profiles
(SNP) per unit length quantified under light microscopy [41].
2.4. Corneal nerve density
Adult (20e30 g) female Swiss Webster mice (Envigo, CA, USA) were
maintained 3e4 per cage on TEK-Fresh bedding (7099, Envigo) in an
AALAC-accredited vivarium under a 12hr light:dark cycle with free
access to diet (5001, LabDiet, MO, USA) and municipal water. A
randomly selected cohort of mice was made diabetic (non-fasting
blood glucose >15 mmol/l) by injection of STZ (75 mg/kg i.p. on 2
consecutive days) following overnight fast. This cohort was maintained
untreated for 8 weeks, along with the remaining age- and sex-
matched control mice. After 8 weeks of diabetes, the cohort was
divided into 2 groups of mice, one of which (N ¼ 10) received daily
delivery of IGF-1 to one eye by eye-drop (50 ml of 25 ng/ml solution in
0.9% saline) while the other diabetic group (N ¼ 9) and the controlhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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group (N ¼ 9) received saline vehicle alone. Treatment was given
between 8 and 10 am each day to manually restrained unanesthetized
animals in their home cage and continued for 4 weeks. No mice died
during the study period, and, at study end, all STZ-injected mice
remained hyperglycemic (non-fasting blood glucose >15 mmol/l).
Corneal nerves of the sub-basal nerve plexus were imaged in
isofluorane-anesthetized mice at 3 time points: before onset of dia-
betes, at week 8 of diabetes, and after 4 weeks of treatment using a
Heidelberg Retina Tomograph 3 with Rostock Cornea Module (Hei-
delberg Engineering, Heidelberg, Germany). Images were collected
from randomly selected animals by an investigator unaware of the
treatment groups and the image stack from each animal was coded.
Nerve occupancy of 5 consecutive images (2 mm intervals) of the cornea
between the superficial corneal epithelium and the stroma was
calculated using an 8  8 grid superimposed on randomized and
coded images [42], as described in detail elsewhere [41]. These studies
were carried out using protocols approved by the Institutional Animal
Care and Use Committee of the University of California, San Diego.
2.5. Adult DRG sensory neuron culture
DRGs were isolated from adult male Sprague-Dawley (300e350 g)
rats and dissociated using previously described methods [43]. Neurons
were cultured in no-glucose Hams F12 media supplemented with
Bottenstein’s N2 without insulin (0.1 mg/ml transferrin, 20 nM pro-
gesterone, 100 mM putrescine, 30 nM sodium selenite 0.1 mg/ml BSA;
all additives were from Sigma, St Louis, MO, USA; culture medium was
from Caisson labs, USA). DRG neurons from control rats were cultured
in the presence of 5 mM D-glucose and DRG neurons derived from
STZ-induced diabetic rats with 25 mM D-glucose. No neurotrophins or
insulin was added to any DRG cultures. The following pharmacological
inhibitors were used: Compound C, a selective and reversible AMPK
inhibitor (Abcam, Cambridge, MA, USA), MK-2206, a highly selective
pan-Akt inhibitor (Santa Cruz Biotechnology, Texas, USA), U0126, a
selective non-competitive inhibitor of MAP kinase kinase (Abcam,
Cambridge, MA, USA), and STO-609, a selective CaMKKb inhibitor
(Santa Cruz Biotechnology, Texas, USA).
2.6. AMPK isoform-specific knockdown
DRG neurons were dissociated and subjected to AMPK isoform-
specific knockdown according to the instruction manual of the
Amaxa Rat Neuron Nucleofector Kit (Lonza Inc., Basel, Switzerland).
Briefly, the neuron pellet was resuspended at room temperature in
100 ml of Nucleofector solution with 200 nM siRNA specific to
AMPKa1, 50-CGAGUUGACUGGACAUAAATT-3’ (siRNA ID:194424,
Thermo Scientific, Pittsburgh, PA, USA), or AMPKa2, 50-GGUUGA-
CAAUCGGAGCUAUTT-3’ (siRNA ID:s134962, Thermo Scientific, Pitts-
burgh, PA, USA), or a scrambled siRNA (Cat #:4390843, Thermo
Scientific, Pittsburgh, PA, USA) as a negative control. The suspension
was transferred into a certified cuvette and Nucleofector program O-
003 on Amaxa Nucleofector machine (Lonza Inc., Basel, Switzerland)
was used to electroporate/transfect the cells with the corresponding
siRNA. Neurons were then plated for further experimentation.
2.7. Luciferase-based ATP assay in DRG culture
To measure ATP production by DRG neurons, Luminescent ATP
detection assay kit (ab113849: Abcam, Cambridge, MA, USA) was
used. In brief, cultured DRG neurons and an ATP standard dilution
series were treated with detergent supplied in the kit and shaken for
5 min. A solution containing D-Luciferin and firefly luciferase were
added to the reaction mix and shaken on a plate stirrer for 5 min. After
10 min adaptation to the dark, luminescence from luciferase activityMOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comwas measured and recorded using the Glomax-multi detection system
(Promega, Wisconsin, USA). A standard curve was plotted and lumi-
nescent units from each sample were interpolated in order to calculate
the absolute ATP concentration per mg of total protein lysate.
2.8. Quantitative Western blotting
Rat DRG neurons were harvested from culture or isolated intact from
adult rats and then homogenized in ice-cold RIPA buffer containing:
25 mM Tris pH ¼ 8, 150 mM NaCl, 0.1% SDS, 0.5% sodium deox-
ycholate, 1% Triton X-100 and protease phosphatase inhibitors. Pro-
teins (2e20 mg total protein/lane) were resolved and separated via
10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE). The proteins were subsequently transferred to a nitro-
cellulose membrane (Bio-Rad, CA, USA) using Trans-Blot Turbo
Transfer System (Bio-Rad, CA, USA) and immunoblotted with specific
antibodies against pP70S6K T389 (1:1000, Cell Signaling Technology,
Massachussetts, USA), pAkt S473 (1:1000, Santa Cruz Biotechnology,
Texas, USA), total Akt (1:1000, Abcam, Cambridge, MA, USA), pAMPK
T172 (1:1000, Cell Signaling Technology, Massachussetts, USA), total
AMPK (1:800, Santa Cruz Biotechnology, Texas, USA), total OXPHOS
(1:2000, MitoSciences, Abcam, Cambridge, MA, USA), PGC-1a
(1:1000, Abcam), pACC S79 (1:1000, Cell Signaling Technology,
Massachussetts, USA) and total ERK (1:1000, Santa Cruz Biotech-
nology, Texas, USA). Of note, total protein bands were captured by
chemiluminescent imaging of the blot after gel activation (TGX Stain-
Free FastCast Acrylamide Solutions, Bio-Rad, CA, USA) in addition to
the use of T-ERK levels for target protein normalization (to adjust for
loading). The secondary antibodies were HRP-conjugated goat anti-
rabbit IgG (H þ L) or goat anti-mouse IgG (H þ L) from Jackson
ImmunoResearch Laboratories, PA, USA. The blots were incubated in
ECL Advance (GE Healthcare) and imaged using a Bio-Rad ChemiDoc
image analyzer (Bio-Rad, CA, USA).
2.9. Real-time PCR array
RNA was extracted from cultured neurons or previously frozen tissue
samples using TRIzol Reagent (Invitrogen, California, USA). Com-
plementary DNA (cDNA) was synthesized from RNA samples by using
the iScript gDNA Clear cDNA Synthesis Kit (Bio-Rad, CA, USA) ac-
cording to the manufacturer’s instructions. Quantitative real-time PCR
(QRT-PCR) was performed using iQ SYBR Green Supermix (Bio-
Rad, CA, USA) or Bright Green Master mix (Abmgood Co., Richmond,
Canada) compatible with the iQ5 Cycler machine (Bio-Rad, CA, USA).
The DDCt method was used to quantify gene expression. The mRNA
level of GAPDH and B2m were used for normalization.
2.10. Mitochondrial DNA/Nuclear DNA (mtDNA/nDNA) ratio
Total DNA was extracted from DRGs by using a modified salting-out
DNA extraction method and subjected to QRT-PCR using iQ
SYBR Green Supermix (Bio-Rad, CA, USA). To calculate mtDNA/nDNA
ratio, we designed primers specific to D-loop regions on rat mito-
chondrial DNA, and to ApoB and B2m genes on the rat nuclear DNA.
PCR product size and specificity were validated using melt curve and
4% agarose gel (Supplementary Figure 1A and B).
2.11. Mitochondrial respiration in cultured neurons
An XF24 analyzer (Seahorse Biosciences, Billerica, MA, USA) was used
to measure the basal level of mitochondrial oxygen consumption rate
(OCR), the maximal respiration, the spare respiratory capacity and the
coupling efficiency. In short, DRG culture medium was changed 1 h
before the assay to unbuffered DMEM (Dulbecco’s modified Eagle’s
medium, pH 7.4) supplemented with 1 mM sodium pyruvate, andaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 151
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used. Four mitochondrial complex inhibitors including oligomycin
(1 mM), FCCP (1 mM) and rotenone (1 mM) þ antimycin A (1 mM) were
injected sequentially through ports in the Seahorse Flux Pak cartridges.
Oligomycin acts as an irreversible ATP synthase inhibitor, FCCP as an
uncoupler, rotenone as Complex I inhibitor, and antimycin A as an
inhibitor of Complex III of the mitochondrial electron transport system.
After OCR measurement, cells were subjected to protein assay (DC
protein assay, BioRad, USA) for normalization purpose and, in some
cases, Western blotting. OCR measures from each well were
normalized to total protein levels and are presented as pmoles/min/mg
protein.
2.12. Neurite outgrowth in DRG cultures
DRG neurons were cultured on glass coverslips. Then, they were fixed
with 4% paraformaldehyde in PBS (pH 7.4) for 15 min at room tem-
perature then permeabilized with 0.3% Triton X-100 in PBS for 5 min.
Neurons were incubated with 5% BSA in PBS for 1 h and with neuron-
specific b-tubulin III antibody (1:1000; from Sigma, St Louis, MO, USA)
overnight. Following three washes with PBS, cells were incubated with
Cy3-conjugated secondary antibody (1:1000, Jackson ImmunoR-
esearch Laboratories Inc., PA, USA) for 1 h at room temperature.
Coverslips were mounted on slides using VECTASHIELD antifade
mounting medium with DAPI (Vectorlabs, Inc., CA, USA) and imaged
using a Carl Zeiss Axioscope-2 upright fluorescence microscope
equipped with AxioVision3 software. The fluorescent signal was
collected as total pixel area for neurites and was measured by the high
throughput NeurphologyJ plugin in ImageJ software after image
enhancement. Total pixel area was normalized to number of cell bodies
to calculate total neurite outgrowth per neuron.
2.13. Mitochondrial isolation and enzymatic activity of respiratory
complexes I and IV in DRG
DRG tissues were homogenized in mitochondrial isolation buffer (MIB)
consisting of 70 mM sucrose, 210 mM mannitol, 5.0 mM HEPES PH
7.2, 1.0 mM EGTA, and 0.5% (w/v) fatty acid free BSA using a Dounce
homogenizer. Supernatant from a double centrifugation of the tissue at
800 g for 15 min was centrifuged twice at 8000 g for 10 min and the
pellet subjected to enzymatic activity assays. Enzymatic activity of
cytochrome c oxidase (a subunit of Complex IV of the mitochondrial
electron transport system) was measured by a temperature controlled
Ultrospec 2100 UVevisible spectrophotometer equipped with Bio-
chrom Swift II software (Biopharmacia Biotech). Briefly, 0.02% lauryl
maltoside was mixed with 10 mg purified mitochondria and incubated
for 1 min before addition of 40 mM reduced cytochrome c and 50 mM
KPi to the mixture. The resulting absorbance decrease of reduced
cytochrome c at 550 nm was monitored for 2 min [44]. Enzymatic
activity of mitochondrial Complex I was measured according to the
instruction manual of the kit (Cat #:K968-100, BioVision, California,
USA). Data was collected at 5 min by reading the absorbance of the
mixture (10 mg mitochondria, Complex I assay buffer, Decylubiquinone
and Complex I dye) at 600 nm using a Ultrospec 2100 UV-visible
spectrophotometer and the kinetic reduction of Complex I dye was
calculated as Complex I activity.
2.14. Metabolomic analysis of nerve
The tibial nerve tissue from rats was utilized for biochemical ana-
lyses. The nerve (10e30 mg) was homogenized with 500 ml ultra-
pure water (Milli-Q H2O, EMDMillipore, Billerica, USA) using a bead
homogenizer (Omni Bead Ruptor 24, OMNI, USA). The same volume
of methanol (500 ml) was added to the homogenized tissue, and the152 MOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. Tmixture was vortexed, sonicated and centrifuged at 10500 g for
5 min. The supernatant was dried under a gentle flow of nitrogen,
and reconstituted in 100 ml deionized water:methanol (1:1) con-
taining 150 ng of each of the following internal standards: L-Tryp-
tophan-d5, L-Valine-d8, L-Alanine-d4, L-Leucine-d10, Citric Acid-d4
and D-Fructose (all from Sigma, USA). Metabolomics analysis was
performed on a 1290 Infinity Agilent high performance liquid chro-
matography (HPLC) system coupled to a 6538 UHD Accurate Quad-
rupole time-of-flight liquid chromatography/mass spectrometry (Q-
TOF LC/MS) from Agilent Technologies (Santa Clara, CA, USA)
equipped with a dual electrospray ionization source as described
elsewhere [45]. A Zorbax SB-Aq 4.6  100 mm, 1.8 U, 600 bar
column (Agilent Technologies) was used to separate metabolites
while the column temperature was maintained at 55 C. In brief, a
sample size of 2 ml was injected into the Zorbax column by main-
taining the HPLC flow rate at 0.6 ml/min. The mass detection was
operated using dual electrospray with reference ions of m/z
121.050873 and 922.009798 for positive mode, and m/z 119.03632
and 980.016375 for negative mode. Targeted MS/MS mode was
used to identify potential biomarkers using Agilent MassHunter
Qualitative (MHQ, B.07) and Mass Profiler Professional (MPP, 12.6.1).
The Molecular Feature Extraction (MFE) parameters were set to allow
the extraction of detected features satisfying absolute abundances of
more than 4000 counts. The data were normalized using a percentile
shift algorithm set to 75 and were adjusted to the baseline values of
the median of all samples.
2.15. Statistical analysis
Data were analyzed using two-tailed Student’s t-tests or one-way
ANOVA followed by Tukey’s or Dunnett’s post hoc tests, as appro-
priate and indicated (GraphPad Prism 7, GraphPad Software). A P
value < 0.05 was considered to be significant. The HeatMap was
made using GraphPad (GraphPad Prism 7, GraphPad Software). The
metabolomics data were analyzed using One Way ANOVA (P < 0.05)
followed by Benjamini-Hochberg multiple testing corrections (Mass
Professional Profiler 12.6.1 and XLSTAT).
3. RESULTS
3.1. IGF-1 enhances mitochondrial respiration and ATP production
in cultured DRG neurons from control and diabetic rats
DRG neurons derived from control rats were cultured and treated with
IGF-1 (10 nM) for 2e24 h. This concentration of IGF-1 does not cross-
occupy the insulin receptor in neurons [46]. Mitochondrial oxygen
consumption rate (OCR) was enhanced at 24 h but not at 2 h or 6 h
(Figure 1A). Bioenergetic parameters of maximal respiration and spare
respiratory capacity were significantly (P < 0.05 and P < 0.01,
respectively) increased 24 h after IGF-1 treatment (Figure 1B).
Nevertheless, IGF-1 did not affect the corrected oligomycin-insensitive
mitochondrial respiration rate (proton leak) (Supplementary Figure 2).
IGF-1 treatment of DRG neurons derived from age-matched diabetic
rats showed up-regulation of mitochondrial maximal respiration at 2 h
and 24 h treatment. Spare respiratory capacity was elevated at least 3-
fold, although not reaching statistical significance, and respiratory
control ratio was significantly increased at 2 h and 24 h of IGF-1
treatment (Figure 1C). To confirm that the mitochondrial OCR was
reflected by similar alterations in cellular ATP production, DRG neurons
from control rats were treated with various doses of IGF-1 for 24 h and
ATP production was measured in live cells. At doses of 1, 10, and
100 nM, but not 0.1 nM, IGF-1 augmented ATP production (P < 0.05)
(Figure 1D).his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Mitochondrial function-related genes are dysregulated in DRG neurons from diabetic rats, and exogenous IGF-1 modulates selective transcripts and
upregulates mitochondrial respiration and ATP production in cultured adult sensory neurons. DRG neurons derived from (A, B, D) adult control or (C) diabetic rats were
treated with/without IGF-1 for 2e24 h. In (A, B, C) the culture plate was then inserted into the Seahorse XF24 Analyzer and oligomycin, FCCP and rotenone þ AA (antimycin A)
added sequentially. In (D) ATP concentration was calculated from proportional luminescent reads by a GloMax-Multi Detection System. Data were normalized to protein con-
centration units per well prior to statistical analysis. Real-time PCR array derived mRNA levels for (F) DRG tissues or (E and G) cultured DRG neurons treated with IGF-1 for 6 h, from
control (ctrl) and diabetic (Db) rats. All mRNA levels were calculated relative to GAPDH or B2m mRNA levels using the DD Ct method. Data are mean  SEM of N¼ 3e5 replicates;
* ¼ p < 0.05 or ** ¼ p < 0.01 or *** ¼ p < 0.001 or **** ¼ p < 0.0001; analyzed by unpaired Student’s t-test or one-way ANOVA with Dunnett’s post-hoc test.
MOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original Article3.2. Genes linked to mitochondrial function were dysregulated in
DRGs from control vs. diabetic rats and in vitro were up-regulated
after IGF-1 treatment
The mRNA levels of a number of genes downstream of IGF-1 signaling
that are linked to mitochondrial function, including Akt2, Akt3,
AMPKa2, UQCRC2, ATP5a1, MFN1, RHOT1, IGF-1, and Kif5B, were
down-regulated in DRG of diabetic rats when compared to control rats
(P < 0.05) (Figure 1F). Some mRNAs including those for Slc2a1
(Glut1), Ppargc1b (PGC-1b) and DNAi1 were up-regulated in DRGs of
diabetic rats (Figure 1F). IGF-1 (10 nM) treatment of cultured DRGs
from control rats for 6 h up-regulated Akt1, Akt2, Akt3, AMPKa1,
AMPKa2, IGF-1R, GSK3b, b-actin, RPS6Kb1 (P70S6K), CPT1a, Glut1,
PFKp, P53, Ppargc1a (PGC-1a), PGC-1b, Srebp1c, MFN1, Nrf1, and
VDAC1 mRNA levels when compared to untreated DRG neuronsFigure 2: IGF-1 treatment increases Akt and AMPK phosphorylation, and the express
were treated with/without 10 nM IGF-1 for (A, B) 15 min-6 h or (C, D) 2e24 h and lysate
quantified and expressed relative to total protein. Complexes I-NDUFB8 and III-UQCRC2 s
* ¼ p < 0.05 or ** ¼ p < 0.01 or *** ¼ p < 0.001 or **** ¼ p < 0.0001 vs ctrl by o
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in vitro with IGF-1 showed a significant (P < 0.05) up-regulation in
mRNA levels of Akt1, Akt2, Akt3, AMPKa1, AMPKa2, GSK3 b, b-actin,
P70S6K, Glut1, PFKp, P53, PGC-1a, PGC-1b, UQCRC2, MTCO1,
ATP5a1, MFN1, Opa1, Drp1, Nrf1, and VDAC1 genes vs. untreated
cultured DRG neurons (Figure 1G).
3.3. IGF-1 augments AMPK, Akt, ACC phosphorylation, and
respiratory protein expression in cultured neurons from control rats
DRG neurons from age matched control rats treated with 10 nM IGF-1
exhibited elevated phosphorylation of Akt (at S473) within 15 min
(Figure 2A,B) and at 2 h this was associated with enhanced
phosphorylation of pP70S6K (a downstream substrate for P-Akt)
(Supplementary Figure 3D). IGF-1 elevated phosphorylation of AMPK ation of electron transport chain proteins. DRG neurons derived from adult control rats
s subjected to Western blotting. Specific proteins from each respiratory Complex were
ubunit proteins were not detectable. Data are mean  SEM of N ¼ 3e4 replicates;
ne-way ANOVA with Dunnett’s post-hoc test.
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T172 and also its phosphorylation target acetyl-Co-A carboxylase (P-
ACC) at 2 h and 6 h (Figure 2A,B). These effects were dose dependent;
with 10 nM IGF-1 giving the highest P-AMPK and P-ACC levels,
whereas 100 nM induced the highest activation of Akt (Supplementary
Figure 3A and B). Treatment for up to 24 h with 10 nM IGF-1 up-
regulated the total protein levels for AMPK and Akt (Supplementary
Figure 3C). The stimulatory effect of IGF-1 on total protein expres-
sion levels for AMPK and Akt at 6 h and 24 h was the reason we
normalized all data to total protein levels. Mitochondrial OXPHOS
proteins, components of the electron transport system (ETS), including
Complex components IV-MTCO1 and V-ATP5a were significantly
elevated after 6 he24 h of IGF-1 treatment (Figure 2C,D). IGF-1 also
elevated these same Complex proteins and Complex II-SDHB in DRG
neuron cultures derived from STZ-induced type 1 diabetic rats
(Supplementary Figure 4A and B). Overall, the impact of IGF-1 on the
level of expression of these respiratory chain proteins was greater in
the diabetic cultures compared with control age-matched cultures.Figure 3: Compound C (AMPK inhibitor) suppresses the IGF-1 upregulation of mit
pretreated with inhibitors 2 h prior to IGF-1 treatment and maintained for 24 h. Mitochond
AMPK inhibitor, MK (MK-2206, 1 mM): Akt inhibitor and STO (STO-609, 1 mM): CaMKKb in
analysis. Data are mean  SEM of N ¼ 3e5 replicates; * ¼ p < 0.05 or ** ¼ p < 0.0
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suppress the IGF-1 induced up-regulation of mitochondrial function
in DRG neurons from control rats
The stimulatory effect of IGF-1 on AMPK activity and respiratory chain
protein expression provided a good rationale to study putative effects
on mitochondrial function. To identify the signaling pathway utilized by
IGF-1 to modulate mitochondrial function, DRG neurons from control
rats were cultured and pretreated with 1 mM compound C (AMPK in-
hibitor), MK-2206 (Akt inhibitor) or STO-609 (CaMKKb inhibitor) 2 h
prior to 10 nM IGF-1 treatment for 24 h. Seahorse XF24 assay for OCR
revealed that IGF-1 up-regulated mitochondrial function with respect
to augmented maximal respiration and spare respiratory capacity
(Figure 3A,B). This effect was completely suppressed by the AMPK
inhibitor and partially suppressed by the Akt inhibitor (Figure 3A,B). The
CaMKKb inhibitor STO-609 also prevented induction of mitochondrial
function by IGF-1 but this effect did not reach statistical significance
(Figure 3A,B). To specifically knockdown isoforms of AMPK, DRGochondrial respiration. (A, B) DRG neurons derived from control rats were cultured,
rial respiration was measured using Seahorse XF24 Analyzer. CC (compound C, 1 mM):
hibitor. Data were normalized to protein concentration units per well prior to statistical
1; analyzed by one-way ANOVA with Tukey’s post-hoc test.
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Figure 4: IGF-1 acts through AMPKa1 and a2 to augment mitochondrial function and mtDNA copy number. (A, B) DRG neurons derived from adult control rats were
transfected with AMPKa1-or a2-specific siRNAs, cultured for 24 h and treated with/without 10 nM IGF-1 for another 24 h. Mitochondrial respiration was measured using Seahorse
XF24 Analyzer. Data were normalized to protein concentration units per well prior to statistical analysis. (C) DRG neurons from control rats were cultured and treated with different
IGF-1 doses (10 nM and 100 nM) for 24e48 or transfected with AMPKa1-or a2-specific siRNAs, cultured for 24 h and treated with/without 10 nM IGF-1 for another 24 h mtDNA/
nDNA ratio was analyzed using Real-Time PCR and calculated using the DDCt method. Data are mean  SEM of N ¼ 3e5 replicates; * ¼ p < 0.05 or ** ¼ p < 0.01; analyzed by
one-way ANOVA with Tukey’s or Dunnett’s post-hoc test.
Original Articleneurons were also transfected with siRNAs specific to AMPKa1 or
AMPKa2 (and in combination) for 24 h prior to IGF-1 treatment for
another 24 h. AMPK knockdown efficiencies were 75e80% for the
specific isoform mRNAs and 73% for the total AMPK protein when both
siRNAs were combined (Supplementary Figure 5AeC). 2D gel elec-
trophoresis revealed that the isoforms of AMPKa1 (mw 63.97 kDa) and
AMPKa2 (mw 62.26 kDa) could be visualized (Supplementary
Figure 5D). Supplementary Figure 5D and E shows that siRNA
knockdown for each isoform was relatively specific. SiRNA to AMPKa1
caused a 77% knockdown and only reduced AMPKa2 by 16%
(Supplementary Figure 5F). For siRNA to AMPKa2, the values were
61% for its own isoform and 16% for the AMPKa1. SDS-PAGE revealed
effective knockdown of phosphorylated AMPK and its target P-ACC
with the combined siRNAs in the presence/absence of IGF-1 for 24 h
(Supplementary Figure 6A). Under the same experimental conditions
siRNA to AMPKa1 blocked phosphorylated AMPK. However, its target156 MOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. TP-ACC was not significantly affected (Supplementary Figure 6B). With
the same experimental paradigm OCR measurements showed sup-
pression of IGF-1-driven up-regulation of maximal respiration and
spare respiratory capacity in neurons treated with AMPKa1 siRNA
(Figure 4A,B) and AMPKa1a2 siRNAs combined (data not shown), but
not with siRNA to AMPKa2 (Supplementary Figure 7AeD).
3.5. AMPK knockdown and Akt inhibitor impede IGF-1
enhancement of neurite outgrowth and mtDNA copy number in DRG
cultures from control rats
To investigate the inhibitory effect of AMPK on mitochondrial DNA copy
number and neurite outgrowth, DRG cultures derived from control rats
were transfected with siRNA to AMPKa1 or a2 and treated with IGF-1.
IGF-1 (10 nM or 100 nM) significantly (P < 0.05) increased mtDNA
copy number after 24 h and 48 h (Figure 4C). This effect of IGF-1 on
mtDNA was significantly suppressed following treatment with siRNA tohis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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AMPKa2 (Figure 4C). Knockdown of either AMPKa1 or AMPKa2 iso-
forms also prevented the IGF-1 enhancement of neurite outgrowth
(Figure 5A). In a complementary experiment, neurite outgrowth was
enhanced by IGF-1 treatment (P < 0.01) and pretreatment with Akt
inhibitor or AMPK inhibitor Compound C suppressed this neuritogenic
effect of IGF-1 (Figure 5B).
3.6. Topical IGF-1 to the eye of diabetic mice reversed the loss of
corneal nerve profiles
To address whether the relatively rapid effects of IGF-1 on regulation of
mitochondrial respiration and neurite outgrowth from adult sensory
neurons in vitro predict neurotrophic and neuroprotective properties
in vivo, we delivered IGF-1 topically to the eye of STZ-induced diabetic
mice daily for 4 weeks, following 8 weeks of diabetes. Nerve density of
the sub-basal nerve plexus was measured iteratively by corneal
confocal microscopy across the study period. Nerve density did not
change over the 12-week study period in control mice (Figure 5CeD).
Eight weeks of diabetes induced a mild reduction in nerve density that
progressed in the subsequent 4 weeks. Initiation of topical IGF-1
treatment prevented this progression such that by the end of the
study the vehicle-treated diabetic group had values that were signifi-
cantly (P < 0.05) lower than the IGF-1 treated group.
3.7. IGF-1 therapy reverses thermal hypoalgesia and corrects
impaired activities of mitochondrial Complexes I and IV in DRG of
diabetic rats
Age-matched control and STZ-induced diabetic rats were maintained
for 3 months; then, a cohort of diabetic rats received injections of
human recombinant IGF-1 (20 mg/rat per day s.c.) for the final 11
weeks (Figure 6A). Body weight, blood glucose, and glycated hemo-
globin values were not any different between untreated and IGF-1-
treated diabetic rats (Supplemental Table 1). Thermal testing on the
hind paw was performed at three time points and revealed develop-
ment of hypoalgesia in diabetic rats and significant improvement in the
IGF-1-treated diabetic rats at the end of study (Figure 6A). Analysis of
IENF density and SNP levels in the hind paw revealed no significant
loss of fibers at the end of this study and no effect of IGF-1 treatment
on IENF whereas a significant rise in SNP profiles was observed
compared to control rats (Figure 6B). Mitochondria isolated from DRGs
of diabetic rats exhibited depressed activity levels of mitochondrial
Complexes I and IV compared with age matched control and these
activities were significantly elevated by IGF-1 therapy (Figure 6C).
3.8. IGF-1 therapy increases the expression of PGC-1a and
respiratory chain proteins and up-regulates AMPK, Akt, and P70S6K
phosphorylation in DRG of diabetic rats
Due to low tissue availability, each animal group was divided into
different sub-groups to perform Western blotting, enzymatic assay,
and mRNA measurements on DRGs. Levels of expression of mito-
chondrial Complex IV-MTCO1 and Complex V-ATP5a, and PGC-1a
proteins were suppressed in DRGs derived from diabetic rats by
approximately 40% and these deficits were prevented by IGF-1 therapy
(Figure 7A). IGF-I therapy also significantly increased the phosphory-
lation of critical effector proteins upstream of mitochondria including
AMPK and P70S6K compared to both control and untreated diabetic
rats, while a trend of elevated Akt activation was also observed
(P ¼ 0.08 vs. control: Figure 7B). It should be noted, that only a partial
depression of P-AMPK and P-P70S6K levels were observed in DRGs of
the diabetic group versus age-matched control in this study. Consistent
with Western blotting data, mRNA levels of AMPKa2 isoform, Complex
III-UQCRC2, and Nrf-1 were restored in diabetic rat DRGs after IGF-IMOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comtherapy (Supplementary Figure 8). AMPKa1, Akt2 and Akt3 mRNAs
were not significantly different between groups (Supplementary
Figure 8).
3.9. IGF-1 therapy reinstates components of the Krebs cycle,
amino acid metabolism, ketosis, and oxidant status but does not
correct aberrant glucose metabolism in tibial nerve of diabetic rats
A targeted metabolomics approach was used to monitor 35 selected
metabolites (Supplemental Table 2) related to energy generation by
mitochondrial function, carbohydrate metabolism and protein meta-
bolism, as recently reported [47]. A total of 13 metabolites were
significantly different and exhibited a similar trend between the 3
groups (Figure 8A). The metabolomics analysis of tibial nerve tissues
showed that Krebs cycle intermediates including fumaric acid, succinic
acid, malic acid and citric acid, and free amino acids or fragmented
peptides such as leucine, aspartic acid, and Ala-Cys-Asp, were
significantly (P < 0.05) up-regulated in nerves of diabetic rats and
were returned to the normal range with IGF-1 therapy (Figure 8A). IGF-
1 injections did not correct the levels of sorbitol, glucose and
myoinositol 4-phosphate, which all represent aberrant glucose meta-
bolism (Figure 8AeB), indicating that IGF-1 did not alter glucose up-
take or metabolism within the local environment of the nerve. However,
diabetes-induced elevation of oxidized glutathione and ketone bodies
including b-hydroxy butyric acid in nerve was reduced by IGF-1
treatment of diabetic animals (Figure 8A). Other metabolites such as
isocitrate (TCA metabolite), homoserine (amino acid precursor), and
acryloylglycine (fatty acid metabolism) did not differ or show any
consistent trends between groups (Supplemental Table 2). The Krebs
cycle metabolites, free amino acids, ketone bodies, and oxidized
glutathione levels showed similar trends, as illustrated for citric and
aspartic acid (Figure 8CeD).
4. DISCUSSION
We demonstrate for the first time that IGF-1 activates and up-regulates
AMPK to augment mitochondrial function, ATP production, mtDNA copy
number, and expression of ETS proteins in cultured rat DRG neurons.
IGF-1 utilizes this AMPK pathway and, possibly in parallel, the Akt
pathway to drive axonal outgrowth. Further, we show that IGF-1
therapy prevented diabetes-induced progressive loss of sensory
nerves in the cornea and ameliorated paw thermal hypoalgesia.
Correction of these clinically relevant endpoints was associated with
suppression of build-up of TCA intermediates in nerve and optimization
of mitochondrial phenotype in the DRG of type 1 diabetic rats. The
stimulatory effect of IGF-1 upon mitochondrial oxygen consumption
rate can be explained by signaling via the AMPKa1 isoform. The
elevation in mtDNA copy number revealed the involvement of AMPKa2
isoform downstream from IGF-1 signaling.
For more than two decades, a variety of studies have demonstrated
that IGF-1 promotes neurite outgrowth and protects from multiple
functional and structural indices of diabetic neuropathy in animal
models [2,9,10]. The emergence of corneal confocal microscopy as a
technique to visualize human sensory nerves in situ has provided a
non-invasive and sensitive biomarker of DSPN that offers the oppor-
tunity to track progression of neuropathy and efficacy of therapeutic
interventions [48]. Diabetic rodents also develop loss of corneal nerves
[42,49] and topical delivery of potential therapies to the eye provides a
useful translational model that bridges in vitro and traditional in vivo
therapeutic studies. Our demonstration that topical delivery of IGF-1
prevented progressive corneal nerve loss in diabetic mice provides
in vivo validation of our in vitro model using adult sensory neuronaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 157
Figure 5: AMPK and Akt inhibition suppresses the axonal regeneration triggered by IGF-I in cultured DRGs from rats and topical IGF-1 prevents progressive loss of
corneal nerves in diabetic mice. DRG neurons derived from adult control rats were (A) transfected with AMPKa1-or a2-specific siRNAs, cultured for 24 h or (B) pretreated
with inhibitors for 2 h and treated with/without 10 nM IGF-1 for another 24 h. b-tubulin III immunostaining was used to stain sensory neurons and NeurphologyJ was used for
automated neurite tracing. CC (compound C, 1 mM): AMPK inhibitor and MK (MK-2206, 1 mM): Akt inhibitor. Total neurite outgrowth data is presented relative to neuron number.
Data are mean  SEM of N ¼ 4 replicates; * ¼ p < 0.05 or ** ¼ p < 0.01 or **** ¼ p < 0.0001; analyzed by one-way ANOVA with Tukey’s post-hoc test. (C) Reveals the
time line for the topical delivery of IGF-1 to the eye of STZ-induced diabetic mice. (D) Line chart showing nerve density (as % occupancy) in the sub-basal nerve plexus of
control (blue line), diabetic (STZ: red line) and IGF-1 treated diabetic (STZ þ IGF-1; green line) mice at 0, 8 and 12 weeks of diabetes. IGF-1 treatment was initiated at 8 weeks.
Data are group mean  SEM of N ¼ 9e10/group. At week 12 * ¼ p < 0.05 for Db vs Db þ IGF-1 group and **p¼<0.01 for Db vs age matched control group by two-way
ANOVA with Tukey’s post-hoc test.
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Figure 6: IGF-1 therapy restored the activity of Complexes I and IV and prevented thermal hypoalgesia in diabetic rats. Control (ctrl), diabetic (Db) and IGF-1-treated
diabetic (Db þ IGF-1) rats were tested for their thermal response latency according to the timeline in (A). (B) IENF and SNP were analyzed in hind paw footskin in the three
groups of animals. (C) DRG tissues from control, diabetic and IGF-1-treated diabetic rats were isolated and subjected to Complex I and Complex IV enzymatic activity assays. Data
are in mU/mg tissue. In (A, B and C) data are mean  SEM of N ¼ 5e10; * ¼ p < 0.05 or ** ¼ p < 0.01 or *** ¼ p < 0.001 or **** ¼ p < 0.0001; analyzed by one-way ANOVA
or two-way ANOVA with Tukey’s post-hoc test.cultures and adds a novel index of the therapeutic potential of IGF-1
against a structural manifestation of DSPN using an assay that
reflects the human condition.
The mechanisms through which IGF-1 operates to implement nerve
growth and repair are not completely understood. It has been proposed
that optimal mitochondrial function is a key factor for axonal outgrowth
and repair [50,51]. For instance, modulating mitochondrial dynamics
by overexpression of MFN-2 or inhibition of DRP-1 regulated the di-
rection and rate of neurite outgrowth in cultured retinal ganglion cells
from rat embryos [52]. Mitochondrial biogenesis triggered by the
AMPK-PGC-1a-Nrf1 pathway and energy supplementation was
required for axonal outgrowth in rat cortical neurons [53]. Resveratrol,
an activator of AMPK, drives axonal outgrowth and was protective
against diabetic neuropathy in STZ-induced diabetic rats [44,54].
Growth factors IL-1b, IL-17A, ciliary neurotrophic factor, and insulin
enhanced mitochondrial function and promoted neurite outgrowth,
which correlated with protection from development of DSPN in animal
models of type 1 diabetes [39,55e57]. Studies with modulators of
heat shock protein function revealed that improved mitochondrialMOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comfunction was associated with prevention and reversal of diabetic
neuropathy in type 1 and type 2 models of diabetes [58,59]. In the
present work in cultured DRG neurons, we demonstrate the novel
finding that a physiologically relevant concentration of IGF-1, which
does not stimulate the insulin receptor [46], up-regulated mitochon-
drial respiration together with a dose-dependent stimulation of ATP
production.
Recent studies also report IGF-1-mediated optimization of mitochon-
drial phenotype in other cell types and diseases. IGF-1 therapy cor-
rected mitochondrial ATPase activity and inhibited caspase 3 and 9
activation in liver cells from aging rats [60]. Glutamine knock-in in
striatal cells from the mutant Huntingtin (mHtt) mouse displayed a
reduction in ROS production and caspase 3 activity and an elevation in
Tfam and mitochondrial-encoded cytochrome c oxidase II proteins
when treated with IGF-1 [35]. In cancer cell lines, exogenous IGF-1
sustains cell viability by stimulating mitochondrial biogenesis and
BNIP3-induced mitophagy [61]. In the current study, in cultured DRG
neurons derived from control or diabetic rats, IGF-1 exerted a novel
up-regulatory effect on mitochondrial respiration, with a significantaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 159
Figure 7: IGF-1 therapy restored the expression of PGC-1a and ETS proteins and up-regulated AMPK, P70S6K, and Akt phosphorylation in diabetic rats. DRG tissues
from control (Ctrl), diabetic (Db) and IGF-1-treated diabetic (Db þ IGF-1) rats were isolated and subjected to (A, B) Western blotting. Western blot band intensity of target proteins
was normalized to total ERK bands of the same blot. Data are mean  SEM of N ¼ 5e7 animals; * ¼ p < 0.05 or ** ¼ p < 0.01; analyzed by one-way ANOVA with Tukey’s post-
hoc test.
Original Articlestimulatory effect on spare, or reserve, respiratory capacity. This effect
occurred over 24 h in control cultures and in diabetic cultures was
triggered within 2 h. This may suggest that IGF-1 enhances the
electrochemical gradient, as observed previously with insulin in DRG
cultures [62], and aerobic glucose metabolism to elevate mitochondrial
oxygen consumption rate [63e65]. In contrast to mitochondrial basal
respiration, spare respiratory capacity is normally utilized when cells
have excessive ATP demands or are stressed, as under chronic hy-
perglycemia. It is most likely that defects in expression or activity of
respiratory chain complexes (or supercomplex formation) in diabetic
conditions, essentially nutrient stress, drives suppression of spare
respiratory capacity thus inducing an energy deficit [38,66,67]. IGF-1
may raise spare respiratory capacity through high ATP demand due to
accelerated neurite outgrowth (thus optimizing the electrochemical
gradient), and/or by normalizing aerobic glucose metabolism and/or
via AMPK-dependent modulation of gene expression of ETS
components.
Comparative mRNA quantitation of selective genes revealed that IGF-1,
AMPK, and Akt isoforms, ATP5a1, MFN-1, and RHOT-1 were sup-
pressed in DRG in diabetic rats. IGF-1 treatment of cultured DRGs from
both control and diabetic rats improved the expression of these dys-
regulated genes with a higher impact in DRG neurons derived from160 MOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. Tdiabetic rats. The most prominent finding of our gene expression
analysis was that IGF-1 up-regulated AMPK (a1 and a2) and Akt (Akt1,
Akt2, and Akt3) functional isoforms in cultured DRGs derived from
diabetic rats. The transcriptional upregulation of these genes by IGF-1
in 6 h could be the main driving factor for enhanced mitochondrial
respiration after 24 h IGF-1 treatment in cultured DRGs from both
control and diabetic rats. Nevertheless, this does not seem to be the
case for enhanced mitochondrial respiration after 2 h IGF-1 treatment,
which is observed in diabetic cultures implying the involvement of
post-translational modifications of metabolism-regulating proteins
including AMPK and Akt.
AMPK and Akt pathways are modulated by IGF-1 in other cell types. In
vascular smooth muscle cells, IGF-1 activates Akt to suppress AMPK
activity by stimulating AMPK S485 phosphorylation, thus instigating
AMPK T172 dephosphorylation [29]. There are two common upstream
kinases, LKB-1 and CaMKKb, known to phosphorylate AMPK on its
activation site, T172, and activate this enzyme [68,69]. Our preliminary
data (not shown) reveal that LKB-1 was not activated by IGF-1, and
CaMKKb inhibition by STO-609 did not significantly affect AMPK
phosphorylation/activity (data not shown) or mitochondrial function in
the presence of IGF-1 (Fig. 4B). In addition, we have preliminary data
showing that IGF-1 did not induce a rise in intracellular Ca2þ inhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 8: IGF-1 therapy reinstates the Krebs cycle, amino acid metabolism, ketosis and oxidant status in tibial nerve of diabetic rats. Tibial nerve tissues from control
(Ctrl), diabetic (Db) and IGF-1-treated diabetic (Db þ IGF-1) rats were dissected and weighed. Total metabolites were extracted using a methanol-water mixture, dried and
subjected to metabolomic analysis using an HPLC system coupled to time-of-flight liquid chromatography/mass spectrometry. Normalized intensity value of each compound was
estimated by using internal standards (L-Tryptophan-d5, L-Valine-d8, L-Alanine-d4, L-Leucine-d10, Citric Acid-d4, and D-Fructose). The final value for each metabolite was
normalized to its corresponding tibial nerve weight and illustrated in (A) HeatMap. The trends for (B) sorbitol, (C) citric acid and (D) aspartic acid are shown as examples. Data are
mean  SEM of N ¼ 9e12 animals; * ¼ p < 0.05; analyzed by one-way ANOVA, followed by Benjamini-Hochberg multiple testing corrections.cultured DRG neurons (where a rise in Ca2þ could be surmised to
trigger activation of CaMKKb). AMPK is also reported to be phos-
phorylated on T172 and activated in an ATM-dependent manner by
IGF-1 in HeLa, PANC-1 and TIG103 cell lines [28] and so future studies
will focus on this pathway.
Among different pharmacological inhibitors used to block IGF-1
downstream effectors, the AMPK inhibitor Compound C completely
abolished the IGF-1-mediated up-regulation of mitochondrial maximal
respiration and spare respiratory capacity. Neurite outgrowth was also
blocked (Fig. 6). SiRNA-based inhibition of the AMPKa1 isoform, but
not AMPKa2 isoform, exhibited a similar suppression of the IGF-1
enhancement of mitochondrial respiration and neurite outgrowth.
The IGF-1 stimulation of mitochondrial DNA copy number was blocked
by either AMPKa2 or AMPKa1 knockdown, which implicates both
isoforms in mtDNA replication. A variety of functions have been re-
ported for these two AMPK isoforms in other tissues. In striatal cells in
mice with Huntington’s disease (HD), accumulated Huntingtin resulted
in AMPKa1 over-activation and nuclear translocation causing cell
death through down-regulation of Bcl-2 [70]. AMPKa1 promotes
contractile function of cardiomyocytes by phosphorylating troponin I
[71], and myogenesis through myogenin gene expression [72].
AMPKa2 knock-out mice show deficient Complex I activity and lowerMOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comcardiolipin content correlating with decreased cardiolipin synthetic
enzymes in cardiomyocytes [73]. In endothelial cells, AMPKa2 acti-
vates anti-inflammatory pathways by phosphorylating PARP-1 and
induction of Bcl-6 [74].
Acute (30 min) intrathecal application of IGF-1 activated Akt in DRG and
this effect was diminished in ob/ob type 2 diabetic mice [75]. In our
in vitro studies the Akt inhibitor, MK-2206, suppressed the IGF-1
dependent augmentation of mitochondrial function and neurite
outgrowth (Figure 4B and 6). Previous work in smooth muscle cells and
cancer cell lines revealed an inhibitory effect of Akt on AMPK via
phosphorylation on S485/S487 and subsequent suppression of
phosphorylation on T172 [29,76]. Moreover, we also found that
inhibiting Akt results in higher AMPK T172 phosphorylation in cultured
DRGs (data not shown). However, we have observed that the Akt in-
hibitor suppressed the IGF-1 up-regulation of mtDNA copy number
(data not shown). In the present study, IGF-1 enhanced phosphoryla-
tion of P70S6K (Supplementary Figure 3D) and Akt directly elevates
P70S6K activity and eukaryotic translation initiation factor 4E (eIF4E)-
binding protein 1 (4E-BP1) function to augment ETS gene expression
[77]. Thus, these studies utilizing pharmacological blockade of Akt
reveal (i) in DRG neurons treated with IGF-1 Akt is acting upstream
from AMPK to suppress AMPK activity, and (ii) upon IGF-1 treatment,access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 161
Original ArticleAkt is mediating parallel or alternative pathways from AMPK that
regulate mitochondrial function and neurite outgrowth.
Previous studies reveal a role of impaired IGF-1 signaling in the eti-
ology of diabetic neuropathy, or as a protective factor [6,7,24]. Mice
with overexpression of neuron-specific IGF binding protein 5 (IGFBP5:
an inhibitory IGF binding protein) or with depleted IGF1R expression
displayed a progressive neurodegeneration similar to that seen in
diabetic neuropathy. These deficits included motor axonopathy and
sensory disorders such as thermal hypoalgesia and intra-epidermal
nerve fiber loss [24]. Osmotic minipump implants releasing 4.2e
4.8 mg/day IGF-1 or IGF-2 for two weeks prevented hyperalgesia and
promoted nerve regeneration in STZ-diabetic rats that had a sciatic
nerve crush injury [17,19]. In a similar study, STZ-induced diabetic rats
exhibited loss of IENF after three months of diabetes, which was
prevented by one-month intrathecal delivery of IGF-1 [20]. Five
micromolar (5 mM) intrathecal infusion of IGF-1 for one month also
improved sensory and motor nerve conduction velocities in diabetic
rats [21].
We previously reported a significant loss of nerves of paw skin and
concurrent hypoalgesia in 5 month diabetic rats and that insulin im-
plants for the last four months prevented IENF loss and thermal
hypoalgesia without correcting hyperglycemia [39]. In the present
study, maintaining diabetic rats for 5 months did not cause significant
nerve fiber loss in the foot skin compared to age-matched control rats,
despite concurrent thermal hypoalgesia. There is precedence for this
disassociation as thermal hypoalgesia precedes detectable IENF loss in
STZ-diabetic mice [78]. It is notable that while our STZ-injected rats
were clearly hyperglycemic, they were not in a state of extreme
catabolic dominance as they gained weight over the study period and
appear to model a slowly progressing neuropathy reflective of the
human condition. The amelioration of thermal hypoalgesia by IGF-1 in
diabetic rats could be due to enhanced sensitivity of afferents via such
known properties as stimulation of T-type channels [79] or sensiti-
zation and translocation of the vanilloid receptor [80]. Alternately, as
IGF-1 enhances substance P and CGRP expression in DRG cultures
[81], it may protect against the diabetes-induced depletion of
sensory neuron neuropeptide expression [82] and stimulus-evoked
spinal release [83] that is associated with early stages of thermal
hypoalgesia [78].
Nutrient flux analysis in db/db type 2 diabetic mice at 24 weeks of age
showed an increase in flux of TCA intermediates in kidney but a
decrease in sciatic nerve [84]. Metabolomic analysis of tibial nerves in
the current study exhibited an increase in TCA intermediates in diabetic
rats. Thus, if reduced flux of metabolites is occurring [84], this build-up
of TCA intermediates suggests that a deficiency in ETS electron flow
and/or enzyme activities is causing impaired utilization of the excessive
available energy sources provided by the Krebs cycle under diabetic
conditions. The diabetes-induced suppression of spare respiratory
capacity combined with reduced ETS protein expression and activity of
Complexes I and IV support the last statement. Despite no effect on up-
regulated intracellular sorbitol and glucose in nerve in diabetes, IGF-1
therapy reinstated ketosis, lowered TCA intermediate build-up, and
normalized oxidant status. Moreover, increased free amino acids or
fragmented peptides in tibial nerves of diabetic rats demonstrate
disturbed protein synthesis and metabolism, which were restored by
IGF-1 therapy, correlating with higher phosphorylation of P70S6K in
DRGs.
Given the established role of IGF-1 in neurite outgrowth, differentiation,
and development, a plethora of nervous system-related diseases
including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis,
amyotrophic lateral sclerosis, Fragile X syndrome, and Rett syndrome162 MOLECULAR METABOLISM 20 (2019) 149e165  2018 The Authors. Published by Elsevier GmbH. Thave become candidates for IGF-1 therapy [85]. A double-blind clinical
trial of IGF-1 therapy in ALS patients receiving IGF-1 (0.5e3 mg/kg
every two weeks for 40 weeks) resulted in beneficial effects with no
adverse events [86]. A phase 1 clinical trial of IGF-1 therapy (40e
120 mg/kg twice daily for 4 weeks) in 12 girls with Rett syndrome
improved measures of anxiety, mood, and apnea with no serious
adverse effects [87]. IGF-1 therapy remains a potential therapeutic
option in diabetic neuropathy but has been hindered by other potential
systemic actions of the peptide. Our studies reveal a novel aspect of
IGF-1 signaling to augment the AMPK pathway to drive nerve repair.
Specific targeting of the IGF-1 signaling axis in neurons could offer an
alternative or complementary approach to treating neurological
disease.
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